COMTVal158Met polymorphism is associated with ecstasy (MDMA)-induced psychotic symptoms in the Turkish population

References

1. 1.↵
   1. Karlsen SN,
   2. Spigset O,
   3. Slørdal L

   . The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3, 4-methylenedioxymethamphetamine. Basic & clinical pharmacology & toxicology 2008; 102: 15–24.

   OpenUrl
2. 2.↵
   1. Han DD,
   2. Gu HH

   . Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC pharmacology 2006; 6: 1–7.

   OpenUrl
3. 3.↵
   1. Quinton MS,
   2. Yamamoto BK

   . Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 2006; 8: E337–E347.

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Virani S,
   2. Daya GN,
   3. Brainch N,
   4. Kotapati VP,
   5. Zaveri D,
   6. Ahmed S

   . Persistent Psychosis due to Single Dose of Ecstasy. Cureus 2018; 10: e3058.

   OpenUrl
5. 5.↵
   1. Potash MN,
   2. Gordon KA,
   3. Conrad KL

   . Persistent psychosis and medical complications after a single ingestion of MDMA “Ecstasy”: a case report and review of the literature. Psychiatry (Edgmont) 2009; 6: 40–44.

   OpenUrlPubMed
6. 6.↵
   1. Chen J,
   2. Lipska BK,
   3. Halim N,
   4. Ma QD,
   5. Matsumoto M,
   6. Melhem S, et al.

   Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75: 807–821.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Lachman HM

   . Does COMT val158met affect behavioral phenotypes: yes, no, maybe? Neuropsychopharmacology 2008; 33: 3027–3029.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Hosák L

   . Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur Psychiatry 2007; 22: 276–281.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.
   1. Oyaci Y,
   2. Aytac HM,
   3. Pasin O,
   4. Cetinay Aydin P,
   5. Pehlivan S

   . Detection of altered methylation of MB-COMT promotor and DRD2 gene in cannabinoid or synthetic cannabinoid use disorder regarding gene variants and clinical parameters. J Addict Dis 2021; 1–19.
10. 10.↵
    1. Pehlivan S,
    2. Aydin PÇ,
    3. Aytaç HM,
    4. Uysal MA,
    5. Sever Ü,
    6. Pehlivan M

    . Investigation of Catechol-O-Methyltransferase and Cannabinoid Receptor 2 gene variants in tobacco use disorder or tobacco use disorder and schizophrenia comorbidity. Anatolian Journal of Psychiatry 2020; 21: 572–578.

    OpenUrl
11. 11.↵
    1. Kirov G,
    2. Murphy K,
    3. Arranz M,
    4. Jones I,
    5. McCandles F,
    6. Kunugi H, et al.

    Low activity allele of catechol-O-methyltransferase gene associated with rapid cycling bipolar disorder. Mol Psychiatry 1998; 3: 342–345.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Strous RD,
    2. Nolan KA,
    3. Lapidus R,
    4. Diaz L,
    5. Saito T,
    6. Lachman HM

    . Aggressive behavior in schizophrenia is associated with the low enzyme activity COMT polymorphism: a replication study. Am J Med Genet B Neuropsychiatr Genet 2003; 120B: 29–34.

    OpenUrl
13. 13.↵
    1. Pehlivan S,
    2. Aytac HM,
    3. Kurnaz S,
    4. Pehlivan M,
    5. Cetinay Aydin P

    . Evaluation of COMT (rs4680), CNR2 (rs2501432), CNR2 (rs2229579), UCP2 (rs659366), and IL-17 (rs763780) gene variants in synthetic cannabinoid use disorder patients. Journal of Addictive Diseases 2020: 1–11.
14. 14.
    1. Tammimäki AE,
    2. Männistö PT

    . Are genetic variants of COMT associated with addiction? Pharmacogenet Genomics 2010; 20: 717–741.

    OpenUrlPubMedWeb of Science
15. 15.↵
    1. Jugurnauth SK,
    2. Chen CK,
    3. Barnes MR,
    4. Li T,
    5. Lin SK,
    6. Liu HC, et al.

    A COMT gene haplotype associated with methamphetamine abuse. Pharmacogenet Genomics 2011; 21: 731–740.

    OpenUrlPubMed
16. 16.↵
    1. Association WM

    . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191–2194.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Baclig MO,
    2. Predicala RZ,
    3. Mapua CA,
    4. Lozano-Kühne JP,
    5. Daroy MLG,
    6. Natividad FF, et al.

    Allelic and genotype frequencies of catechol-O-methyltransferase (Val158Met) and CYP2D6* 10 (Pro34Ser) single nucleotide polymorphisms in the Philippines. Int J Mol Epidemiol Genet 2012; 3: 115–121.

    OpenUrlPubMed
18. 18.↵
    1. Lee W-C,
    2. Wang L-Y

    . Simple formulas for gauging the potential impacts of population stratification bias. Am J Epidemiol 2008; 167: 86–89.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Lohoff FW,
    2. Weller AE,
    3. Bloch PJ,
    4. Nall AH,
    5. Ferraro TN,
    6. Kampman KM, et al.

    Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence. Neuropsychopharmacology 2008; 33: 3078–3084.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Mizuno Y,
    2. Jung M,
    3. Fujisawa TX,
    4. Takiguchi S,
    5. Shimada K,
    6. Saito DN, et al.

    Catechol-O-methyltransferase polymorphism is associated with the cortico-cerebellar functional connectivity of executive function in children with attention-deficit/hyperactivity disorder. Sci Rep 2017; 7: 4850.

    OpenUrl
21. 21.↵
    1. Hosák L

    . Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur Psychiatry 2007; 22: 276–281.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Schilt T,
    2. Koeter MW,
    3. de Win MM,
    4. Zinkstok JR,
    5. van Amelsvoort TA,
    6. Schmand B, et al.

    The effect of Ecstasy on memory is moderated by a functional polymorphism in the cathechol-O-methyltransferase (COMT) gene. Eur Neuropsychopharmacol 2009; 19: 116–124.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Fagundo AB,
    2. Cuyàs E,
    3. Verdejo-Garcia A,
    4. Khymenets O,
    5. Langohr K,
    6. Martín-Santos R, et al.

    The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users. J Psychopharmacol 2010; 24: 1381–1393.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Li T,
    2. Chen Ck,
    3. Hu X,
    4. Ball D,
    5. Lin SK,
    6. Chen W, et al.

    Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet 2004; 129B: 120–124.

    OpenUrl
25. 25.↵
    1. Taylor S

    . Association between COMT Val158Met and psychiatric disorders: A comprehensive meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2018; 177: 199–210.

    OpenUrl
26. 26.↵
    1. Hosak L,
    2. Libiger J,
    3. Cizek L,
    4. Beranek M,
    5. Cermakova E

    . The COMT Val158Met polymorphism is associated with novelty seeking in Czech methamphetamine abusers: preliminary results. Neuro Endocrinol Lett 2006; 27: 799–802.

    OpenUrlPubMed
27. 27.↵
    1. Bousman C,
    2. Cherner M,
    3. Atkinson J,
    4. Heaton R,
    5. Grant I,
    6. Everall I, et al.

    COMT Val158Met polymorphism, executive dysfunction, and sexual risk behavior in the context of HIV infection and methamphetamine dependence. Interdiscip Perspect Infect Dis 2010; 2010: 678648.

    OpenUrlPubMed
28. 28.↵
    1. Suzuki A,
    2. Nakamura K,
    3. Sekine Y,
    4. Minabe Y,
    5. Takei N,
    6. Suzuki K, et al.

    An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder. Psychiatr Genet 2006; 16: 133–138.

    OpenUrlCrossRefPubMedWeb of Science
29. 29.↵
    1. Egan MF,
    2. Goldberg TE,
    3. Kolachana BS,
    4. Callicott JH,
    5. Mazzanti CM,
    6. Straub RE, et al.

    Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98: 6917–6922.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. Mattay VS,
    2. Goldberg TE,
    3. Fera F,
    4. Hariri AR,
    5. Tessitore A,
    6. Egan MF, et al.

    Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003; 100: 6186–6191.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Sara GE,
    2. Large MM,
    3. Matheson SL,
    4. Burgess PM,
    5. Malhi GS,
    6. Whiteford HA, et al.

    Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation. Aust N Z J Psychiatry 2015; 49: 106–117.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. McKetin R,
    2. McLaren J,
    3. Lubman DI,
    4. Hides L

    . The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006; 101: 1473–1478.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Curran C,
    2. Byrappa N,
    3. McBride A

    . Stimulant psychosis: systematic review. Br J Psychiatry 2004; 185: 196–204.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    1. Virani S,
    2. Daya GN,
    3. Brainch N,
    4. Kotapati VP,
    5. Zaveri D,
    6. Ahmed S

    . Persistent Psychosis due to Single Dose of Ecstasy. Cureus 2018; 10: e3058.

    OpenUrl
35. 35.↵
    1. Duman B,
    2. Sedes N,
    3. Baskak B

    . Additive Effects of Former Methylenedioxymethamphetamine and Cannabis Use on Subclinical Psychotic Symptoms. Noro Psikiyatr Ars 2017; 54: 38–42.

    OpenUrl
36. 36.↵
    1. Hosák L,
    2. Serý O,
    3. Beranek M,
    4. Alda M

    . Lack of association between the Val158Met catechol-O-methyltransferase gene polymorphism and methamphetamine dependence. Neuro Endocrinol Lett 2011; 32: 469–474.

    OpenUrlPubMed
37. 37.↵
    1. Zumárraga M,
    2. Arrúe A,
    3. Basterreche N,
    4. Macías I,
    5. Catalán A,
    6. Madrazo A, et al.

    COMT haplotypes, catecholamine metabolites in plasma and clinical response in schizophrenic and bipolar patients. Pharmacogenomics 2016; 17: 837–851.

    OpenUrl
38. 38.↵
    1. Meyer-Lindenberg A,
    2. Kohn PD,
    3. Kolachana B,
    4. Kippenhan S,
    5. McInerney-Leo A,
    6. Nussbaum R, et al.

    Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005; 8: 594–596.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.↵
    1. Tunbridge EM,
    2. Harrison PJ,
    3. Weinberger DR

    . Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 2006; 60: 141–151.

    OpenUrlCrossRefPubMedWeb of Science
40. 40.↵
    1. Gouzoulis-Mayfrank E,
    2. Daumann J

    . Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 2006; 101: 348–361.

    OpenUrlCrossRefPubMedWeb of Science
41. 41.↵
    1. Kanthasamy A,
    2. Sprague J,
    3. Shotwell J,
    4. Nichols D

    . Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience 2002; 114: 917–924.

    OpenUrlCrossRefPubMedWeb of Science